RxDoctor Payments Data

Sanjib Mohanty, MD

Gastroenterology · Charlotte, NCNPI 1972561157

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Pentax Of America, Inc. at 27.9% of the total. Reporting peaked in 2024 at $369 and has fallen 84.1% since, to $59 in 2025. That places this record below the midpoint for gastroenterology clinicians in NC, where the typical reported total is $1,694.

$543in general payments, 2019–2025

Across 18 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pentax Of America, Inc.$152
  • Enterra Medical, Inc.$145
  • Medtronic$71
  • AbbVie$42
  • Johnson & Johnson$27
  • Nestle Healthcare Nutrition Inc.$18
  • plus $88 from 6 others
$307,507in research payments, 2019–2025

Across 167 payments — averaging $1841.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$92K
  • Roche Products Limited$75K
  • Gilead$68K
  • Janssen Research & Development, LLC$38K
  • Takeda Pharmaceuticals U.S.A., Inc.$29K
  • Eli Lilly$6K

What the payments were for

  • Food & beverage$53198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$543 in reported general payments places this provider in the 25th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$219,114
Medicare patients
306
Services billed
7,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin20$68,924
LinzessLinaclotide16$12,828
Mesalamine14$7,287
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates111$7,007
Budesonide DrBudesonide18$1,894
Omeprazole82$1,320
Pantoprazole Sodium83$1,032
Famotidine47$716
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg19$347
Doxycycline Hyclate11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$42$12,82816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →